BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Accenture
US Department of Justice
Baxter
Cantor Fitzgerald
Chubb
Teva
Farmers Insurance
Fuji

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,216,174

« Back to Dashboard

Which drugs does patent 9,216,174 protect, and when does it expire?

Patent 9,216,174 protects XIIDRA and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.
Summary for Patent: 9,216,174
Title:Modulators of cellular adhesion
Abstract: The present invention provides compounds having formula (I): ##STR00001## and pharmaceutically acceptable derivatives thereof, wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
Inventor(s): Shen; Wang (San Mateo, CA), Barr; Kenneth (Boston, MA), Oslob; Johan D. (Sunnyvale, CA), Zhong; Min (Foster City, CA)
Assignee: SARCODE BIOSCIENCE INC. (Brisbane, CA)
Application Number:13/969,968
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,216,174

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,216,174

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,989,626 Modulators of cellular adhesion ➤ Subscribe
7,314,938 Modulators of cellular adhesion ➤ Subscribe
7,745,460 Modulators of cellular adhesion ➤ Subscribe
8,071,617 Modulators of cellular adhesion ➤ Subscribe
7,928,122 Modulators of cellular adhesion ➤ Subscribe
7,790,743 Modulators of cellular adhesion ➤ Subscribe
9,248,126 Modulators of cellular adhesion ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,216,174

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2016147908 ➤ Subscribe
Spain 2383525 ➤ Subscribe
Hong Kong 1095815 ➤ Subscribe
Japan 2007513081 ➤ Subscribe
Japan 5105578 ➤ Subscribe
Japan 2013010778 ➤ Subscribe
Japan 5840582 ➤ Subscribe
Japan 2014196353 ➤ Subscribe
European Patent Office 1682537 ➤ Subscribe
Denmark 1682537 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Argus Health
AstraZeneca
Novartis
Accenture
Cantor Fitzgerald
Chubb
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot